Voyager Therapeutics Inc. gained 22.21% on Tuesday, following a global strategic collaboration with AbbVie to develop potential new treatments for Alzheimer's disease and other Tau-related neurodegenerative diseases using its gene therapy platform. Voyager will perform research and preclinical development of vectorized antibodies directed against tau, a hallmark Alzheimer's protein.
from RTT - Biotech http://ift.tt/2EC3iCD
via IFTTT
No comments:
Post a Comment